Skip to content

US · NIKI · BIOTECHNOLOGY

Niki BioSolutions, Inc. (NIKI) intrinsic value and stock valuation

$1.57as of 2026-11-21 · Mkt cap 764.69K

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Niki BioSolutions, Inc. DCF and intrinsic value

InvestorsCraft values NIKI with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from NIKI’s statements →

Niki BioSolutions, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Princeton, NJ 08540 aptorumgroup.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$0.00
20172025
Net income
-$-1.36M
20172025
Free cash flow
-$-1.84M
20172025
Total equity
$13.8M-18.4% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$0.00$0.00$430K$1.3M$1.54M
Operating income-$-1.82M-$-3.8M-$-10.6M-$-17.51M-$-19.21M
Net income-$-1.36M-$-4.27M-$-2.83M-$-9.8M-$-25.05M
EPSd-$-19.43M-$-85.4M-$-56.6M-$-245M-$-626.25M
Operating cash flow-$-1.84M-$-1.19M-$-7.72M-$-12.32M-$-14.65M
Capital expenditure$0.00$0.00-$0.00-$-190K-$-140K
Free cash flow-$-1.84M-$-1.19M-$-7.73M-$-12.51M-$-14.79M
Total assets$18.7M$16.1M$20.6M$20.9M$21.9M
Total debt$3.44M$3.35M$3.28M$6.85M$220K
Net debt-$-10K$2.48M$1.28M$4.97M-$-7.91M
Total equity$13.8M$11.8M$15.4M$7.83M$17.5M
Cash and short-term investments$3.45M$870K$2.01M$1.99M$8.5M
Income statement
20252024202320222021
Revenue$0.00$0.00$430K$1.3M$1.54M
Cost of revenue$0.00$260K$420K$1.22M$1.46M
Gross profit$0.00-$-260K$10K$80K$80K
Research and development expenses$350K$1.94M$5.2M$9.22M$10.9M
Selling, general and administrative expenses$1.64M$1.47M$4.42M$7.97M$8.03M
Other expenses-$-170K$130K$1M$70K$390K
Operating expenses$1.82M$3.54M$10.6M$17.3M$19.3M
Cost and expenses$1.82M$3.8M$11M$18.8M$20.8M
Interest income$0.00$0.00$0.00$150K$0.00
Interest expense$100K$150K$120K$0.00$90K
Depreciation and amortization$0.00$260K$1.12M$1.21M$1.19M
Ebitda-$-1.82M-$-3.76M-$-9.48M-$-10.32M-$-25.83M
Operating income-$-1.82M-$-3.8M-$-10.6M-$-17.51M-$-19.21M
Total other income/expenses, net$440K-$-360K$6.26M$5.98M-$-7.91M
Income before tax-$-1.38M-$-4.16M-$-4.34M-$-11.53M-$-27.11M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-1.36M-$-4.27M-$-2.83M-$-9.8M-$-25.05M
Weighted average shares outstanding$70K$50K$50K$40K$40K
Weighted average diluted shares outstanding$70K$50K$50K$40K$40K
Balance sheet
20252024202320222021
Cash and short-term investments$3.45M$870K$2.01M$1.99M$8.5M
Net receivables$0.00$0.00$70K$1.39M$3.56M
Inventory$0.00$0.00$0.00$30K$40K
Total current assets$3.59M$960K$2.48M$7.07M$12.7M
Property, plant and equipment, net$0.00$0.00$1.85M$3.17M$4.03M
Goodwill and intangible assets$0.00$0.00$150K$750K$880K
Long-term investments$15.1M$15.1M$16.1M$9.74M$4.16M
Total non-current assets$15.1M$15.2M$18.2M$13.8M$9.22M
Total assets$18.7M$16.1M$20.6M$20.9M$21.9M
Accounts payable$0.00$0.00$0.00$0.00$0.00
Short-term debt$3.44M$3.34M$130K$6.32M$400K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$4.59M$4.34M$2.1M$12.5M$4.38M
Long-term debt$0.00$10K$3.16M$530K$20K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$310K$10K$3.16M$530K$20K
Capital lease obligations$20K$120K$220K$340K$220K
Total liabilities$4.9M$4.35M$5.26M$13M$4.4M
Common stock$0.00$0.00$0.00$35.7M$35.6M
Retained earnings-$-73.79M-$-72.43M-$-68.16M-$-65.34M-$-55.54M
Accumulated other comprehensive income (loss)-$-90K$90K-$-10K$30K-$0.00
Total equity$13.8M$11.8M$15.4M$7.83M$17.5M
Total investments$15.1M$15.1M$16.1M$9.85M$4.39M
Total debt$3.44M$3.35M$3.28M$6.85M$220K
Net debt-$-10K$2.48M$1.28M$4.97M-$-7.91M
Cash flow statement
20252024202320222021
Net income-$-1.38M-$-4.16M-$-4.34M-$-11.53M-$-27.11M
Depreciation and amortization$0.00$310K$1.38M$1.56M$1.19M
Stock-based compensation$0.00$0.00$1.27M$1.65M$1.68M
Change in working capital-$-100K-$-210K$460K$1.4M$1.02M
Accounts receivable$20K$330K$420K-$-170K-$-20K
Inventory$0.00$0.00$10K$10K$0.00
Accounts payable-$-30K-$-420K$400K$1.92M$860K
Net cash provided by operating activities-$-1.84M-$-1.19M-$-7.72M-$-12.32M-$-14.65M
Investments in property, plant and equipment$0.00$0.00-$0.00-$-190K-$-140K
Acquisitions, net$0.00$0.00$0.00$0.00-$-110K
Net cash used for investing activities$0.00$60K$620K$2.44M$16.5M
Common stock issued$5.07M$0.00$1.58M$10K$4M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$4.42M$0.00$4.09M$6.63M$2.78M
Net change in cash$2.58M-$-1.13M-$-3.01M-$-3.25M$4.64M
Cash at end of period$3.45M$870K$2.01M$5.01M$8.26M
Operating cash flow-$-1.84M-$-1.19M-$-7.72M-$-12.32M-$-14.65M
Capital expenditure$0.00$0.00-$0.00-$-190K-$-140K
Free cash flow-$-1.84M-$-1.19M-$-7.73M-$-12.51M-$-14.79M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Niki BioSolutions, Inc.

        Niki BioSolutions is a biopharmaceutical company that resulted from the merger of Aptorum Group and DiamiR Biosciences. The company focuses on developing and commercializing a diverse portfolio of therapeutic and diagnostic assets. Its work spans from treatments for diseases with unmet medical needs, particularly in oncology and infectious diseases, to the development of innovative, blood-based diagnostic tests for brain health and other conditions.

        CEO
        Chung Yuen Huen
        Employees
        0
        Beta
        0.17

        Explore

        Frequently asked questions

        What is the intrinsic value of Niki BioSolutions, Inc. (NIKI)?

        InvestorsCraft does not currently publish an intrinsic value for NIKI. How the IC value is calculated.

        Is NIKI undervalued?

        InvestorsCraft does not publish an undervaluation signal for NIKI at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.